Clinical Trials
Peer-reviewed studies, trial results, and the science as it lands — what the latest psilocybin research actually found, read plainly and without the hype.
Never Miss What Matters
One weekly email. The best psilocybin research, podcasts, and news from trusted sources around the world — no searching required.
Psilocybin for PTSD: Trials, Laws, and Early Evidence
In January 2026, the FDA accepted Compass Pathways’ Investigational New Drug Application to study its synthetic psilocybin compound, COMP360, as a possible therapy for PTSD. A separate randomized…
Psilocybin and Inflammation: What the Research Shows
In a study of 60 healthy adults, a single dose of psilocybin was associated with significantly reduced levels of the inflammatory markers TNF-alpha and IL-6 over the following…
Psilocybin for Anxiety: Ontario Clinical Trial Launches
Kingston Health Sciences Centre in Ontario has launched a regulated clinical trial examining whether psilocybin-assisted therapy can reduce anxiety. The trial is in an early enrollment phase, and…
Psilocybin and Cognition: What 20 Studies Found
A 2024 systematic review pooled 20 studies and 2,959 participants to assess how psilocybin affects thinking. Results were mixed: global cognition and processing speed were largely unchanged in…
Psilocybin for Veteran PTSD: Early Trial Remission Rates
A clinical trial examined psilocybin-assisted therapy in veterans diagnosed with PTSD and reported striking remission rates among participants. This is early-phase human research, and the full details of…
Psilocybin for OCD: single dose eases symptoms for months
In the first placebo-controlled trial to test psilocybin for obsessive-compulsive disorder, a single dose produced rapid reductions in OCD symptoms among people who had not responded to conventional…
VA and HHS Sign Psychedelic Therapy Partnership for Veterans
The Department of Veterans Affairs and the Department of Health and Human Services signed a memorandum of understanding in July 2026 to expand psychedelic therapy research and ready…
Psilocybin for Parkinson’s: UCSF Pilot Safety Findings
In a small, first-of-its-kind pilot at UC San Francisco, 12 people living with Parkinson’s disease each completed two sessions of psilocybin therapy, one at 10 mg and one…
Psilocybin for Anorexia Nervosa: Early Pilot Signals
In a small single-blind pilot of 21 adult females with anorexia nervosa, researchers at Imperial College London observed statistically significant reductions in eating disorder symptoms and improved motivation…
Psilocybin and the Self: How It Desynchronizes the Brain
In a small pilot study of seven healthy adults, Washington University researchers used fMRI to show that psilocybin dramatically disrupts functional connectivity across the brain, especially in the…
You've Come This Far. Stay Informed.
Join our free weekly newsletter and get the best psilocybin research, medical journals, podcasts, and news — hand-curated from trusted sources around the world and delivered straight to your inbox.